• Medacta kept its FY 2026 outlook for 10%-14% constant-currency revenue growth.
• It still targets about 50 bps expansion in adjusted EBITDA margin versus 27.9% a year earlier, in constant currency.
• H1 revenue rose to EUR 368 million, up 9.7% in constant currency or 7% in euros.
• Mid-term view unchanged for 2024-2027E revenue CAGR of 12%-15% in constant currency, with a gradual adjusted EBITDA margin improvement versus 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2374900_en) on July 31, 2026, and is solely responsible for the information contained therein.